Abstract
ObjectiveWe aimed to establish a method to determine whether peripheral blood NCAM/amphiphysin 1 dual-labeled exosomal proteins and microRNA might be serve as a marker for the diagnosis of Alzheimer's disease.MethodsIt was a multicenter study using a two-stage design. The subjects included 45 SCD, 50 aMCI, 40 AD patients, and 30 controls in the discovery stage; the results were confirmed in the verification stage (47 SCD, 45 aMCI, 45 AD, and 30 controls). Peripheral blood NCAM single-labeled and NCAM/amphiphysin 1 double-labeled exosomes were captured and detected by immunoassay, respectively.ResultsLevels of Aβ42, Aβ42/40, Tau, P-T181-tau, and miR-29c-3p in plasma NCAM single-labeled and NCAM/amphiphysin 1 double-labeled exosomes of the aMCI and AD groups were significantly higher than those of the SCD group, control group and VaD group (all P<0.05). The levels of Aβ42 and miR-29c-3p in peripheral blood NCAM/amphiphysin 1 dual-labeled exosome was higher than that in the control and VaD groups (all P<0.05). The levels of exosomal Aβ42, Aβ42/40, Tau, P-T181-tau, and miR-29c-3p in peripheral blood were correlated with that in CSF (all P<0.05). ConclusionThis study first provided a method for sorting specific surface marker exosomes using a two-step immune capture technology. The plasma NCAM/amphiphysin 1 dual-labeled exosomal Aβ42/40 and miR-29c-3p had potential advantages in the diagnosis of SCD.